Publications by authors named "Arvind N Dasari"
Recently, organ preservation with total neoadjuvant therapy resulted in substantial progress in the management of locally advanced rectal cancer (LARC). The PROSPECT trial showed noninferiority of de-escalation of radiotherapy for patients with low-risk LARC who do not need abdominoperineal resection. Although these escalation and de-escalation approaches offer more personalized therapeutic approaches, the current state of care for patients with rectal cancer is far from individualized management.
View Article and Find Full Text PDFArticle Synopsis
- Traditional guidelines recommend preserving 700 cc of liver during radiation treatment to minimize the risk of liver failure, but this study explores using SPECT imaging to better identify and protect functional liver tissue in patients with diminished liver volume from previous treatments.
- The phase I trial involved 12 patients with colorectal liver metastases, all having received prior chemotherapy, and assessed safety by monitoring for toxicities after high-dose liver-directed radiotherapy.
- Results showed that incorporating SPECT imaging allowed for safe administration of higher radiation doses without dose-limiting toxicities, achieving a 57% in-field control rate and a 73% overall survival rate after one year.
Article Synopsis
- The study focuses on circulating tumor DNA (ctDNA) testing in metastatic colorectal cancer, highlighting the potential for false negatives which may affect treatment decisions.* -
- Researchers developed a Bayesian statistical model using data from two different cohorts to estimate the probability of false negatives, demonstrating its effectiveness in distinguishing true and false test results.* -
- The findings recommend that clinicians utilize this model to assess ctDNA results more effectively, especially when specific mutation frequencies are considered, and provide an open-source application for broader use.*
Purpose: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Methods: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Results: Eight randomized controlled trials met the inclusion criteria for the systematic review.